Curis

CRIS

Market cap $22.7M

Overview Fund Activity

1.82 USD

0.00

0%

At close Updated Sep 12, 4:00 PM EDT

1 day

0%

5 days

6.43%

1 month

10.3%

3 months

-34.3%

6 months

-30.8%

Year to date

-57.08%

1 year

-63.53%

5 years

-91.88%

10 years

-99.28%

About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 33

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

5% more funds holding

Funds holding: 40 [Q1] → 42 (+2) [Q2]

0% more capital invested

Capital invested by funds: $9.8M [Q1] → $9.84M (+$34.6K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

14.14% less ownership

Funds ownership: 55.12% [Q1] → 40.98% (-14.14%) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 3 articles about CRIS published over the past 30 days

Curis, Inc. (CRIS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.

Curis, Inc. (CRIS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.

Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held September 3 – 5, 2025.

Curis to Present at Upcoming Healthcare Conferences in September

The Motley Fool

Curis (CRIS) Q2 Loss Narrows 66%

Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.

Curis (CRIS) Q2 Loss Narrows 66%

Curis, Inc. (CRIS) Q2 2025 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.

Curis, Inc. (CRIS) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $1.99. This compares to a loss of $2.03 per share a year ago.

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis Provides Second Quarter 2025 Business Update

Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.

Curis Provides Second Quarter 2025 Business Update

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

LEXINGTON, Mass. , July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m.

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant").

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™